Idiopathic Pulmonary Fibrosis clinical trials at UCSF
5 in progress, 2 open to eligible people
DWN12088 in Patients With IPF
open to eligible people ages 40 years and up
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
San Francisco, California and other locations
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
open to eligible people ages 40 years and up
Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.
San Francisco, California and other locations
BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
San Francisco, California and other locations
Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Sorry, accepting new patients by invitation only
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
San Francisco, California and other locations
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
Sorry, not yet accepting patients
The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.
San Francisco, California
Our lead scientists for Idiopathic Pulmonary Fibrosis research studies include Erica Farrand, MD.
Last updated: